The results of these tests allow the choice of target therapies specific to each patient (e.g., quantification of BRAF V600 mutations for anti-RAF and anti-MEK target therapies, or BCR-ABL fusion genes for Imatinib treatment in chronic myeloid leukemia or lymphoblastic leukemia acute) [165]. This evidence concerns the gene MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive.